In 2014, the Society for Vascular Surgery (SVS), the European Society for Vascular Surgery (ESVS), and the World Federation of Vascular Societies (WFVS) joined forces to create a new global consortium for clinical practice guidelines in vascular disease. The GVG™ initial project is a guideline on the evaluation and management of chronic limb threatening ischemia (CLTI).

**GVG™ CLTI Guideline Published in June 2019**

The guideline has been jointly published as a supplement of the *Journal of Vascular Surgery* and *European Journal of Vascular and Endovascular Surgery*.

Read the guideline in: JVS Supplement
Global Vascular Guidelines
Published on Society for Vascular Surgery (https://vascular.org)

Read the guideline in: EJVES Supplement

About the Guideline

The guideline aims to establish a new patient-centered, evidence-based framework for clinical decision making in patients with chronic limb threatening ischemia (CLTI). The guideline contains the following chapters:

1. Definitions and nomenclature
2. Global epidemiology and risk factors for CLTI
3. Diagnosis and limb staging in CLT
4. Medical management of the patient with CLTI
5. The Global Limb Anatomical Staging System (GLASS) for CLTI
6. Strategies for revascularization in CLTI
7. Non-revascularization treatments of the limb
8. Biologic and regenerative medicine approaches in CLTI
9. The role of minor and major amputations
10. Post-procedural care and surveillance following infrainguinal revascularization for CLTI
11. Study designs and trial endpoints in CLTI
12. Creating a Center of Excellence for Amputation Prevention

Transparency
Funding for the development of the GVG™ CLTI Guideline is provided by the sponsoring professional societies. A transparent conflict of interest (COI) policy includes full disclosures; a majority of writing group members must be free of any industry income.

Methodology
Evidence reviews are prepared by an independent academic support group. The GRADE system is used to define
both the strength of the recommendation and the level of evidence.

**Co-Editors**
Prof. Andrew Bradbury, MBA, MD, London, UK
Michael S. Conte, MD, San Francisco, CA
Prof. Philippe Kolh, MD, PhD, Liege, Belgium

**Steering Committee Members**
Florian Dick, MD, Berne, Switzerland
Prof. Robert Fitridge, MBBS, FRACS, Adelaide, Australia
Joseph Mills, MD, Houston, TX
Prof. Jean-Baptiste Ricco, MD, PhD, Poitiers, France
Kal R. Suresh MD, FACS, Bangalore, India
John White, MD, Chicago, IL